1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Real-time Estimate Cboe Europe  -  05/16 05:07:03 am EDT
10258.00 GBX   -0.27%
03:56aNetScientific Shares Rise on Successful Completion of AstraZeneca Covid-19 Antibody Test
02:01aPT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation
05/15AstraZeneca's Asthma Drug Cuts Risk Of Severe Exacerbations In Late-stage Study
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca PLC Announces Positive Results from the TOPAZ-1 Phase III Trial

01/19/2022 | 07:33am EDT

AstraZeneca PLC announced Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca's Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC). These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. BTC is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder. Approximately 50,000 people in the US, Europe and Japan and about 210,000 people worldwide are diagnosed with BTC each year. These patients have a poor prognosis, with approximately 5% to 15% of all patients with BTC surviving five years. In a predefined interim analysis, patients treated with Imfinzi in combination with standard-of-care chemotherapy experienced a 20% reduction in the risk of death versus chemotherapy alone (based on a hazard ratio [HR] of 0.80; 95% confidence interval [CI], 0.66-0.97; 2-sided p=0.021). Median OS was 12.8 months versus 11.5 for chemotherapy. An estimated 25% of patients were still alive at two years versus 10% for chemotherapy. Results also showed a 25% reduction in the risk of disease progression or death with Imfinzi plus chemotherapy (HR, 0.75; 95% CI, 0.64-0.89; 2-sided p=0.001). Median PFS was 7.2 months for the combination versus 5.7 for chemotherapy. Patients treated with Imfinzi plus chemotherapy achieved an objective response rate (ORR) of 26.7% versus an ORR of 18.7% for patients treated with chemotherapy alone. Imfinzi plus chemotherapy did not increase the discontinuation rate due to adverse events (AEs) compared to chemotherapy alone. Grade 3 or 4 treatment-related AEs were experienced by 62.7% of patients treated with Imfinzi and chemotherapy, and by 64.9% of patients receiving chemotherapy alone. Treatment-related AEs led to discontinuation in 8.9% of patients treated with the Imfinzi combination versus 11.4% of patients receiving chemotherapy. In December 2020, Imfinzi was granted Orphan Drug Designation in the US for the treatment of BTC. In October 2021, an Independent Data Monitoring Committee recommended the TOPAZ-1 Phase III trial to be unblinded at an interim analysis due to clear evidence of efficacy for Imfinzi plus chemotherapy. An additional presentation featured during the ASCO Gastrointestinal Cancers Symposium will showcase Imfinzi data from the HIMALAYA Phase III trial, demonstrating the potential of this medicine in the treatment of unresectable liver cancer.

ę S&P Capital IQ 2022
All news about ASTRAZENECA PLC
03:56aNetScientific Shares Rise on Successful Completion of AstraZeneca Covid-19 Antibody Tes..
02:01aPT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed..
05/15AstraZeneca's Asthma Drug Cuts Risk Of Severe Exacerbations In Late-stage Study
05/15PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed..
05/13AstraZeneca, Baili Launch Clinical Trial Collaboration for Lung Cancer Drug Combination
05/13Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispec..
05/13Human ventricular progenitor cells promote the formation of new heart tissue following ..
05/13N.Korea gets offers of aid to fight COVID as it lacks vaccines
05/12AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicine..
05/11Sanofi Says Nirsevimab Showed Nearly 80% Efficacy Against Respiratory Syncytial Virus
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 675 M - -
Net income 2022 5 307 M - -
Net Debt 2022 22 509 M - -
P/E ratio 2022 36,8x
Yield 2022 2,34%
Capitalization 195 B 195 B -
EV / Sales 2022 4,98x
EV / Sales 2023 4,55x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 125,85 $
Average target price 144,07 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.53%195 003
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ROCHE HOLDING AG-15.85%258 421